Cat. #: Mab-604031 (0.1mg)

Description:

The CD19 antigen (95kDa) is expressed from the earliest stage of B progenitor development, on all peripheral B cells including germinal centre B cells, and all B cell lines and B cell leukaemia tested. T cell and monocytic cell lines are negative and the antigen is lost on B cell maturation to plasma cells. The antigen is a type I integral membrane glycoprotein whose in vitro inhibition will influence B cell activation and proliferation.

Immunogen/Specificity:

Ni-NTA purified recombinant human CD19 expressed in E. Coli strain M15.

Applications :

Western Blot: Dilution 1: 2000- 5,000 IHC(P): Dilution 1: 100- 1: 400 IHC(F): Dilution 1: 200- 1: 400 ELISA: Propose dilution 1: 10,000. Determining optimal working dilutions by titration test.

Determining optimal working dilutions by titration test.

Formulation

Antibodies are purified by protein A affinity chromatography.

Reference:

1. Rie, M.A. de, J. of Immunol. Methods, 1987. 102 187.

2. Rie, M.A. de, Leukaemia Research, 1988.12: 135. . .

Clone Number: 2E2B6B10 Isotype: IgG2a Species: Human Storage and Stability: stored at -20 C





Figure 1: Western blot analysis using anti-Human CD19 monoclonal antibody against recombinant human CD19 expressed in E. *Coli*.



Human normal lymph node

Figure 2: Immunohistochemical staining of paraffin-embedded human normal lymph node, showing cytoplasmic staining using anti-human CD19 monoclonal antibody. The HRP-second antibody was used before color development with DAB.